Last mentioned: Mar 9, 2026
Pipeline Expansion
Expected utilization of funds to advance additional candidates from the OPERA platform.
Clinical Milestone Expected
Anticipated progress updates on the KRRO-110 Phase 1/2 clinical trial for AATD.
Private Placement Announced
Korro Bio announces the closing of an $85 million oversubscribed private placement.
$85M Private Placement
Company announces oversubscribed funding to accelerate clinical trials.
Platform Validation
Preclinical data for lead AATD program shows high editing efficiency.
Merger Completion
Korro Bio becomes a public entity via merger with Freeline Therapeutics.
Korro Bio has announced an oversubscribed $85 million private placement, signaling strong investor confidence in its proprietary RNA editing platform. This capital injection is expected to extend the company's cash runway and accelerate the clinical development of its lead programs targeting genetic diseases.
Korro Bio has announced an oversubscribed $85 million private placement to accelerate its proprietary RNA editing platform and clinical development. The funding provides a significant runway for the company's lead program, KRRO-110, targeting Alpha-1 Antitrypsin Deficiency.
Korro Bio (NASDAQ: KRRO) has successfully closed an $85 million private placement, signaling strong investor confidence in its proprietary RNA editing platform. The capital infusion is earmarked for the clinical advancement of its lead candidate, KRRO-110, and the expansion of its OPERA platform.